Last reviewed · How we verify
Afluria
At a glance
| Generic name | Afluria |
|---|---|
| Sponsor | University of Massachusetts, Worcester |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues. (EARLY_PHASE1)
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (PHASE3)
- Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects. (PHASE2)
- National Vaccine Adverse Event Reporting Survey and Etiology
- Effect of Influenza Vaccination on IVF Outcomes - IVF (PHASE4)
- Afluria Pregnancy Registry
- Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Afluria CI brief — competitive landscape report
- Afluria updates RSS · CI watch RSS
- University of Massachusetts, Worcester portfolio CI